1. Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms.
- Author
-
Tamtaji OR, Reiter RJ, Alipoor R, Dadgostar E, Kouchaki E, and Asemi Z
- Subjects
- Animals, Apoptosis drug effects, Autophagy drug effects, Disease Models, Animal, Humans, Melatonin pharmacology, Oxidative Stress drug effects, Melatonin therapeutic use, Parkinson Disease drug therapy
- Abstract
Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementation is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on PD in preclinical and clinical studies.
- Published
- 2020
- Full Text
- View/download PDF